由于RNA修饰在广泛的细胞网络和信号通路中具有广泛的调节作用,最近引起了人们的极大关注。在心血管疾病(CVD)中,一些RNA变化,称为“摘要脚本组”更改,存在于所有RNA分子(tRNA,rRNA,mRNA和ncRNAs)。与表观遗传过程不同,影响动脉粥样硬化(AS)的进展,其转录和转录后调控机制尚不清楚。这里,我们描述了主要的表观基因组标志,以提供对AS的新见解,包括M6A,m5C,m1A,m7G,Φ,和A-to-I编辑。此外,我们还包括所有目前已知的RNA-修饰靶向,包括小分子抑制剂或活化剂,主要针对m6A和m5A相关酶设计,如METTL3,FTO,ALKBH5最后,因为只有几种药物,如阿扎胞苷和他泽米托坦,靶向DNA表观基因组,已经被FDA批准,下一个挑战是鉴定靶向RNA表位基因组的分子.迄今为止,三七总皂苷可以通过Wilms\'肿瘤相关蛋白1m6A依赖性减少血管增生。的确,虚拟筛查使我们能够个性化植物分子,大黄酸,通过增加mRNAm6A水平充当FTO抑制剂。在这次审查中,我们强调了与AS相关的RNA表观转录组通路,描述它们的生物学功能和与疾病的联系。对表观转录敏感途径的鉴定可以提供新的机会来发现预测性的,诊断,和精准医学的预后生物标志物。
RNA modifications have recently gained great attention due to their extensive regulatory effects in a wide range of cellular networks and signaling pathways. In cardiovascular diseases (CVDs), several RNA changes, called \"
epitranscriptome\" alterations, are found in all RNA molecules (tRNA, rRNA, mRNA, and ncRNAs). Unlike the epigenetic process, which influences the progression of atherosclerosis (AS), its transcriptional and post-transcriptional regulatory mechanisms are still unknown. Here, we described the main
epitranscriptome signs to provide new insights into AS, including m6A, m5C, m1A, m7G, Ψ, and A-to-I editing. Moreover, we also included all current known RNA-- modifier-targeting, including small molecular inhibitors or activators, mainly designed against m6A- and m5A-related enzymes, such as METTL3, FTO, and ALKBH5. Finally, since only a few drugs, such as azacitidine and tazemetostat, targeting the DNA epigenome, have been approved by the FDA, the next challenge would be to identify molecules for targeting the RNA
epitranscriptome. To date, total Panax notoginseng total saponin could reduce vascular hyperplasia via Wilms\' tumor-associated protein-1 m6A-dependent. Indeed, a virtual screening allowed us to individuate a phytomolecule, the rhein, which acts as an FTO inhibitor by increasing mRNA m6A levels. In this review, we highlighted the RNA
epitranscriptome pathways implicated in AS, describing their biological functions and their connections to the disease. The identification of
epitranscriptome- sensitive pathways could provide novel opportunities to find predictive, diagnostic, and prognostic biomarkers for precision medicine.